8-K: Surmodics Exceeds Expectations in Q1, Raises Full-Year Guidance

Surmodics reported a strong first quarter with a 23% increase in total revenue and has raised its full-year financial guidance.

Summary

• Surmodics reported a 23% increase in total revenue to $30.6 million for the first quarter of fiscal year 2024, compared to $24.9 million in the same period last year.
• Excluding SurVeil DCB license fees, total revenue increased by 25% to $29.6 million.
• Medical Device revenue saw a 24% increase to $23.5 million, driven by a 43% surge in product sales.
• In Vitro Diagnostics (IVD) revenue grew by 18% to $7.0 million.
• The company's GAAP net loss improved significantly to $(0.8) million, compared to $(7.8) million in the prior year.
• Adjusted EBITDA was $3.9 million, a substantial improvement from a loss of $(3.3) million in the same quarter last year.
• Surmodics has updated its fiscal year 2024 revenue guidance to $117 million to $121 million, or 10% to 14% growth excluding SurVeil DCB license fees.
• The company now expects a GAAP diluted loss per share between $(1.40) and $(1.10) for fiscal year 2024.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue growth, improved profitability metrics, and raised guidance. The company's strategic progress and product launches also contribute to the positive outlook. However, the decrease in product gross margin and the overall net loss temper the sentiment slightly.

Positives

• Surmodics exceeded revenue expectations for the first quarter of fiscal year 2024.
• The company experienced strong growth in both its Medical Device and In Vitro Diagnostics segments.
• Medical Device product sales saw a significant increase of 43% year-over-year.
• The company's net loss improved substantially compared to the same quarter last year.
• Adjusted EBITDA showed a significant positive swing, moving from a loss to a profit.
• Surmodics raised its full-year revenue and EPS guidance.
• The company has made significant progress on its strategic objectives for fiscal 2024.
• The launch of the Preside coating technology and positive clinical data for the SurVeil and Sundance DCBs are positive developments.
• The Pounce LP Thrombectomy System has seen successful early clinical use.

Negatives

• Product gross margin decreased to 53.2% from 63.0% due to increased sales of newer products not yet at scale and increased sales of lower margin IVD products.
• The company reported a GAAP net loss of $(0.8) million, although this is a significant improvement year-over-year.
• The company used $10.2 million in cash during the quarter.
• The company's total revenue guidance for fiscal year 2024 represents a decrease of (12)% to (9)% compared to fiscal 2023, although this is due to reduced SurVeil DCB license fees.

Risks

• The company's ability to successfully commercialize its SurVeil DCB, Sundance DCB, and other proprietary products is a risk.
• Surmodics relies on third parties for development, regulatory approval, marketing, and sales of products incorporating their technologies.
• Adverse market conditions could negatively impact the company's cash flows.
• The company's ability to profitably produce and commercialize its vascular intervention products is a risk.
• Supply chain constraints could impact the company's ability to meet demand.
• The company's operating expenses may not be effective in generating profitable revenues.
• Disruptions from the company's plan to reduce cash usage could impact the business.
• The company's future performance is subject to the risk factors outlined in their annual report on Form 10-K.

Future Outlook

Surmodics expects fiscal 2024 total revenue to range from $117 million to $121 million, representing a decrease of (12)% to (9)% compared to fiscal 2023. Excluding SurVeil DCB license fee revenue, Surmodics expects fiscal 2024 total revenue to range from $113 million to $117 million, representing an increase of 10% to 14% compared to fiscal 2023. The company also expects a GAAP diluted loss per share between $(1.40) and $(1.10) and a Non-GAAP diluted loss per share between $(1.17) and $(0.87).

Management Comments

• We delivered total revenue growth in the first quarter that exceeded our expectations, increasing 23% year-over-year 25% excluding SurVeil DCB license fees with impressive performance in both our Medical Device and In Vitro Diagnostics business segments.
• Our Medical Device segment revenue benefited from record product sales, which increased 43% year-over-year fueled by sales of our vascular interventions portfolio, including strong contributions from both our SurVeil DCB and Pounce thrombectomy products.
• Importantly, we were pleased to complement our revenue performance in the quarter with notable year-over-year improvements in our GAAP net loss and Adjusted EBITDA, as well as significant operational progress with respect to each of our three strategic objectives for fiscal 2024.
• We are raising our fiscal 2024 total revenue and EPS guidance today to reflect our financial and operational performance in the first quarter, which supports our conviction in our ability to generate total revenue growth of 10% or higher for the full year, excluding SurVeil DCB license fees.
• We look forward to building on our recent progress by continuing to execute efficiently on our stated strategic objectives in order to foster strong, sustainable, long-term growth and value creation.

Industry Context

Surmodics' strong performance in the medical device and in vitro diagnostics sectors reflects a growing demand for advanced medical technologies. The company's focus on vascular intervention devices and performance coatings aligns with industry trends towards minimally invasive procedures and improved device performance. The positive clinical data for their drug-coated balloons also positions them well in the competitive landscape.

Comparison to Industry Standards

• Surmodics' 23% revenue growth in Q1 is strong compared to many medical device companies, although direct comparisons are difficult without specific competitor data.
• The 43% growth in medical device product sales is particularly notable, suggesting strong market acceptance of their vascular intervention portfolio.
• The improvement in GAAP net loss and Adjusted EBITDA indicates progress towards profitability, which is a key metric for investors in the medical device sector.
• Companies like Medtronic and Abbott, which are larger players in the medical device space, often have more diversified revenue streams, making direct comparisons challenging.
• Surmodics' focus on niche areas like drug-coated balloons and thrombectomy devices allows them to compete effectively in specific market segments.
• The company's updated guidance suggests confidence in their ability to maintain growth momentum, which is a positive signal for investors.

Stakeholder Impact

• Shareholders will likely react positively to the strong financial results and raised guidance.
• Employees may be encouraged by the company's growth and positive outlook.
• Customers will benefit from the company's innovative medical device and diagnostic technologies.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company's improved financial performance favorably.

Next Steps

• Surmodics will continue to execute on its strategic objectives for fiscal 2024.
• The company will focus on commercializing its SurVeil DCB, Sundance DCB, and other proprietary products.
• Surmodics will continue to support customers integrating the Preside coating technology.
• The company will complete limited market evaluation cases for the Pounce venous thrombectomy system and proceed with limited and full commercial launches.
• Surmodics will continue to advance its pipeline of new products and line extensions.

Key Dates

Keywords

Surmodics, Medical Devices, In Vitro Diagnostics, Revenue Growth, Drug-Coated Balloon, Thrombectomy, Financial Results, EBITDA, Guidance, Preside Coating, SurVeil DCB, Pounce Thrombectomy, Vascular Interventions